Citius Oncology's LYMPHIR added to NCCN Guidelines (Category 2A) for CTCL

CITIUS ONCOLOGY, INC.

LYMPHIR (denileukin diftitox-cxdl) included in NCCN Guidelines for relapsed/refractory Cutaneous T-cell Lymphoma as Category 2A recommendation.
FDA-approved therapy targets IL-2 receptor on malignant T-cells; Phase 3 Study 302 supported approval.
CEO Mazur states inclusion may aid adoption and ease reimbursement, especially for CMS coverage.
NCCN Guidelines are widely used for clinical decision-making and payer reimbursement in the U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.